Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform

Partnership supports reimbursement strategy and U.S. commercial expansion for Aclarion’s AI-driven platform for chronic low back pain.Program ...

Aclarion Stockholders Approve All Proposals at 2026 Annual Meeting

Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) ...

Aclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker Study

Award-winning, NIH funded study indicates that immune-associated biological signatures may play a role in some cases of back painNociscan’s ...

Aclarion Rejects Echo Lake Capital’s Unsolicited Acquisition Proposal

Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) ...